<DOC>
	<DOCNO>NCT00807209</DOCNO>
	<brief_summary>To review safety effectiveness two dos compare current standard care .</brief_summary>
	<brief_title>Dose Finding Posterolateral Thoracotomy Study</brief_title>
	<detailed_description>Evaluate efficacy intercostal nerve block use SKY0402 compare epidural bupivacaine HCl subject undergoing posterolateral thoracotomy . The primary outcome metric amount rescue PCA fentanyl administer breakthrough pain first 72 hour .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Men woman â‰¥ 18 year age Screening Visit . Scheduled undergo thoracotomy least 3 inch intercostal incisional length require insertion interrib spreader/retractor primary thoracic noninfectious indication general anesthesia . Able willing receive epidural catheter treatment postoperative pain . American Society Anesthesiology ( ASA ) Physical Class 14 . Able willing comply study visit procedure . Able speak , read , understand language ICF , study questionnaire , instrument use collect subjectreported outcome , order enable accurate appropriate response pain scale require study assessment . Willing capable provide write informed consent . Known metastatic disease type . Known pulmonary infectious disease . Pregnancy , nursing , plan become pregnant study within one month study drug administration . Use following medication within time specify surgery : 1 . Longacting opioids within 3 day . 2 . Any opioid medication within 24 hour . Concurrent painful physical condition concurrent surgery may require analgesic treatment postoperative period pain strictly relate surgical site administer study drug ( e.g. , significant pain joint , chronic neuropathic pain , concurrent abdominal surgery , etc . ) , potential confound postoperative study assessment . Body weight less 50 kilogram ( 110 pound ) . History hypersensitivity idiosyncratic reaction amidetype local anesthetic , opioid medication , epinephrine , sulfites . Contraindication epinephrine , concurrent administration ergottype drug , monoamine oxidase ( MAO ) inhibitor antidepressant tryptoline imipramine type , condition production exacerbation tachycardia could prove fatal ( e.g. , poorly control thyrotoxicosis severe heart disease ) , pathological condition might aggravate effect epinephrine . Administration investigational product within 30 day 5 elimination halflives investigational product , whichever longer , prior study drug administration , plan administration another investigational product procedure subject 's participation study . History , suspect , know addiction abuse illicit drug ( ) , prescription medicine ( ) , alcohol within past 2 year . Uncontrolled anxiety , schizophrenia , psychiatric disorder , opinion Investigator , may interfere study assessment compliance protocol . Significant medical condition laboratory result , opinion Investigator , indicate increase vulnerability study drug procedure , expose subject unreasonable risk result participate clinical trial , : debilitating disease , acute illness , hypotension , partial complete conduction block , impaired cardiac function , untreated hypertension , advance arteriosclerotic heart disease , cerebral vascular insufficiency , preexist abnormal neurological neuromuscular disease ( e.g. , epilepsy , myasthenia gravis ) , advance liver disease , sever renal impairment , advanced diabetes , comorbid condition associate immunocompromised status , blood dyscrasia , HIV/AIDS , recent chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Pain</keyword>
	<keyword>postoperative</keyword>
	<keyword>thoracotomy</keyword>
</DOC>